Colleen Niswender
Last active: 3/3/2020

Profile

I am an Associate Professor of Pharmacology and also currently serve as the Director of Molecular Pharmacology for the Vanderbilt Center for Neuroscience Drug Discovery. During the past year I have focused on the molecular pharmacology of novel allosteric modulators of metabotropic glutamate and muscarinic receptors. These studies have involved high throughput screening, assay development, and in vitro pharmacology experiments to investigate the effects of novel modulators on cellular signaling pathways. I am actively involved in each of the main VCNDD collaborations, including those partnered with the Michael J. Fox Foundation, Seaside Therapeutics, Johnson and Johnson, and the NIH, as well as studies interfacing with the Molecular Libraries Probe Centers Network (MLPCN). In addition to my role as Director of Molecular Pharmacology, I am also the Biology Team Leader for the development of potential clinical candidates for mGluR4 modulation as a treatment of Parkinson’s disease. These studies interface between areas of pharmacology, medicinal chemistry, drug metabolism and pharmacokinetics, in vivo rodent behavioral studies, and toxicology testing. This program is now at the point of licensing these compounds for clinical testing.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Biased M receptor-positive allosteric modulators reveal role of phospholipase D in M-dependent rodent cortical plasticity. Moran SP, Xiang Z, Doyle CA, Maksymetz J, Lv X, Faltin S, Fisher NM, Niswender CM, Rook JM, Lindsley CW, Conn PJ (2019) Sci Signal 12(610)
    › Primary publication · 31796631 (PubMed) · PMC6936752 (PubMed Central)
  2. Discovery of structurally distinct tricyclic M positive allosteric modulator (PAM) chemotypes. Temple KJ, Long MF, Engers JL, Watson KJ, Chang S, Luscombe VB, Rodriguez AL, Niswender CM, Bridges TM, Conn PJ, Engers DW, Lindsley CW (2020) Bioorg Med Chem Lett 30(4): 126811
    › Primary publication · 31787491 (PubMed)
  3. Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M positive allosteric modulator (PAM) chemotype. Temple KJ, Engers JL, Long MF, Watson KJ, Chang S, Luscombe VB, Jenkins MT, Rodriguez AL, Niswender CM, Bridges TM, Conn PJ, Engers DW, Lindsley CW (2020) Bioorg Med Chem Lett 30(3): 126812
    › Primary publication · 31784320 (PubMed)
  4. Discovery of a novel 3,4-dimethylcinnoline carboxamide M positive allosteric modulator (PAM) chemotype via scaffold hopping. Temple KJ, Engers JL, Long MF, Gregro AR, Watson KJ, Chang S, Jenkins MT, Luscombe VB, Rodriguez AL, Niswender CM, Bridges TM, Conn PJ, Engers DW, Lindsley CW (2019) Bioorg Med Chem Lett 29(21): 126678
    › Primary publication · 31537424 (PubMed)
  5. Evaluation of Synthetic Cytochrome P-Mimetic Metalloporphyrins To Facilitate "Biomimetic" Biotransformation of a Series of mGlu Allosteric Ligands. Presley CC, Perry CK, Childress ES, Mulder MJ, Luscombe VB, Rodriguez AL, Niswender CM, Conn PJ, Lindsley CW (2019) ACS Omega 4(7): 12782-12789
    › Primary publication · 31460402 (PubMed) · PMC6690571 (PubMed Central)
  6. Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu NAMs: Challenging SAR, enantiospecific activity and in vivo efficacy. Yamada Y, Yohn SE, Gilliland K, Loch MT, Schulte ML, Rodriguez AL, Blobaum AL, Niswender CM, Jeffrey Conn P, Lindsley CW (2019) Bioorg Med Chem Lett 29(18): 2670-2674
    › Primary publication · 31358468 (PubMed)
  7. mGlu Positive Allosteric Modulators Facilitate Long-Term Potentiation via Disinhibition Mediated by mGlu-Endocannabinoid Signaling. Xiang Z, Lv X, Maksymetz J, Stansley BJ, Ghoshal A, Gogliotti RG, Niswender CM, Lindsley CW, Conn PJ (2019) ACS Pharmacol Transl Sci 2(3): 198-209
    › Primary publication · 31259318 (PubMed) · PMC6591772 (PubMed Central)
  8. SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M PAMs. Chopko TC, Han C, Gregro AR, Engers DW, Felts AS, Poslusney MS, Bollinger KA, Morrison RD, Bubser M, Lamsal A, Luscombe VB, Cho HP, Schnetz-Boutaud NC, Rodriguez AL, Chang S, Daniels JS, Stec DF, Niswender CM, Jones CK, Wood MR, Wood MW, Duggan ME, Brandon NJ, Conn PJ, Bridges TM, Lindsley CW, Melancon BJ (2019) Bioorg Med Chem Lett 29(16): 2224-2228
    › Primary publication · 31248774 (PubMed) · PMC6690795 (PubMed Central)
  9. VU6005806/AZN-00016130, an advanced M positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Engers DW, Melancon BJ, Gregro AR, Bertron JL, Bollinger SR, Felts AS, Konkol LC, Wood MR, Bollinger KA, Luscombe VB, Rodriguez AL, Jones CK, Bubser M, Yohn SE, Wood MW, Brandon NJ, Dugan ME, Niswender CM, Jeffrey Conn P, Bridges TM, Lindsley CW (2019) Bioorg Med Chem Lett 29(14): 1714-1718
    › Primary publication · 31113706 (PubMed)
  10. Surveying heterocycles as amide bioisosteres within a series of mGlu NAMs: Discovery of VU6019278. Reed CW, Washecheck JP, Quitlag MC, Jenkins MT, Rodriguez AL, Engers DW, Blobaum AL, Jeffrey Conn P, Niswender CM, Lindsley CW (2019) Bioorg Med Chem Lett 29(10): 1211-1214
    › Primary publication · 30910459 (PubMed)
  11. A Coordinated Attack: Rett Syndrome Therapeutic Development. Gogliotti RG, Niswender CM (2019) Trends Pharmacol Sci 40(4): 233-236
    › Primary publication · 30905360 (PubMed) · PMC6482467 (PubMed Central)
  12. Discovery of VU2957 (Valiglurax): An mGlu Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, Rodriguez AL, Felts AS, Engers JL, Loch MT, Emmitte KA, Castelhano AL, Kates MJ, Nader MA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW (2019) ACS Med Chem Lett 10(3): 255-260
    › Primary publication · 30891122 (PubMed) · PMC6421540 (PubMed Central)
  13. Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962). Reed CW, Yohn SE, Washecheck JP, Roenfanz HF, Quitalig MC, Luscombe VB, Jenkins MT, Rodriguez AL, Engers DW, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW (2019) J Med Chem 62(3): 1690-1695
    › Primary publication · 30608678 (PubMed) · PMC6501583 (PubMed Central)
  14. Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders. Fisher NM, Seto M, Lindsley CW, Niswender CM (2018) Front Mol Neurosci : 444
    › Primary publication · 30588231 (PubMed) · PMC6302680 (PubMed Central)
  15. Novel M positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands. Poslusney MS, Salovich JM, Wood MR, Melancon BJ, Bollinger KA, Luscombe VB, Rodriguez AL, Engers DW, Bridges TM, Niswender CM, Conn PJ, Lindsley CW (2019) Bioorg Med Chem Lett 29(3): 362-366
    › Primary publication · 30580918 (PubMed) · PMC6690489 (PubMed Central)
  16. The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate. Panarese JD, Engers DW, Wu YJ, Guernon JM, Chun A, Gregro AR, Bender AM, Capstick RA, Wieting JM, Bronson JJ, Macor JE, Westphal R, Soars M, Engers JE, Felts AS, Rodriguez AL, Emmitte KA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW (2019) Bioorg Med Chem Lett 29(2): 342-346
    › Primary publication · 30503632 (PubMed)
  17. Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Felts AS, Bollinger KA, Brassard CJ, Rodriguez AL, Morrison RD, Scott Daniels J, Blobaum AL, Niswender CM, Jones CK, Conn PJ, Emmitte KA, Lindsley CW (2019) Bioorg Med Chem Lett 29(1): 47-50
    › Primary publication · 30446311 (PubMed) · PMC6295259 (PubMed Central)
  18. Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders. Fisher NM, Seto M, Lindsley CW, Niswender CM (2018) Front Mol Neurosci : 387
    › Primary publication · 30405350 (PubMed) · PMC6206046 (PubMed Central)
  19. Discovery of Novel Central Nervous System Penetrant Metabotropic Glutamate Receptor Subtype 2 (mGlu) Negative Allosteric Modulators (NAMs) Based on Functionalized Pyrazolo[1,5- a]pyrimidine-5-carboxamide and Thieno[3,2- b]pyridine-5-carboxamide Cores. Childress ES, Wieting JM, Felts AS, Breiner MM, Long MF, Luscombe VB, Rodriguez AL, Cho HP, Blobaum AL, Niswender CM, Emmitte KA, Conn PJ, Lindsley CW (2019) J Med Chem 62(1): 378-384
    › Primary publication · 30350962 (PubMed)
  20. Activated CaMKII Binds to the mGlu Metabotropic Glutamate Receptor and Modulates Calcium Mobilization. Marks CR, Shonesy BC, Wang X, Stephenson JR, Niswender CM, Colbran RJ (2018) Mol Pharmacol 94(6): 1352-1362
    › Primary publication · 30282777 (PubMed) · PMC6207916 (PubMed Central)
  21. VU6007477, a Novel M PAM Based on a Pyrrolo[2,3-]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events. Engers JL, Childress ES, Long MF, Capstick RA, Luscombe VB, Cho HP, Dickerson JW, Rook JM, Blobaum AL, Niswender CM, Engers DW, Conn PJ, Lindsley CW (2018) ACS Med Chem Lett 9(9): 917-922
    › Primary publication · 30258541 (PubMed) · PMC6142057 (PubMed Central)
  22. Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu). Bollinger SR, Engers DW, Panarese JD, West M, Engers JL, Loch MT, Rodriguez AL, Blobaum AL, Jones CK, Thompson Gray A, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2019) J Med Chem 62(1): 342-358
    › Primary publication · 30247901 (PubMed)
  23. Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M Positive Allosteric Modulators. Engers JL, Bender AM, Kalbfleisch JJ, Cho HP, Lingenfelter KS, Luscombe VB, Han C, Melancon BJ, Blobaum AL, Dickerson JW, Rook JM, Niswender CM, Emmitte KA, Conn PJ, Lindsley CW (2019) ACS Chem Neurosci 10(3): 1035-1042
    › Primary publication · 30086237 (PubMed) · PMC6456254 (PubMed Central)
  24. Corrigendum to "Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]. Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2018) Bioorg Med Chem Lett 28(17): 3014
    › Primary publication · 30076050 (PubMed) · PMC6690053 (PubMed Central)
  25. Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu positive allosteric modulators that mitigate CYP1A2 induction liability. Engers DW, Bollinger SR, Engers JL, Panarese JD, Breiner MM, Gregro A, Blobaum AL, Bronson JJ, Wu YJ, Macor JE, Rodriguez AL, Zamorano R, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2018) Bioorg Med Chem Lett 28(15): 2641-2646
    › Primary publication · 29958762 (PubMed)
  26. The discovery of VU0486846: steep SAR from a series of M PAMs based on a novel benzomorpholine core. Bertron JL, Cho HP, Garcia-Barrantes PM, Panarese JD, Salovich JM, Nance KD, Engers DW, Rook JM, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW (2018) Bioorg Med Chem Lett 28(12): 2175-2179
    › Primary publication · 29754948 (PubMed) · PMC6427922 (PubMed Central)
  27. Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Felts AS, Rodriguez AL, Morrison RD, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA (2018) Bioorg Med Chem Lett 28(10): 1679-1685
    › Primary publication · 29705142 (PubMed) · PMC6142812 (PubMed Central)
  28. A Novel M PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity. Rook JM, Bertron JL, Cho HP, Garcia-Barrantes PM, Moran SP, Maksymetz JT, Nance KD, Dickerson JW, Remke DH, Chang S, Harp JM, Blobaum AL, Niswender CM, Jones CK, Stauffer SR, Conn PJ, Lindsley CW (2018) ACS Chem Neurosci 9(9): 2274-2285
    › Primary publication · 29701957 (PubMed) · PMC6146057 (PubMed Central)
  29. PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems. Moran SP, Cho HP, Maksymetz J, Remke DH, Hanson RM, Niswender CM, Lindsley CW, Rook JM, Conn PJ (2018) ACS Chem Neurosci 9(9): 2218-2224
    › Primary publication · 29683646 (PubMed) · PMC6146053 (PubMed Central)
  30. Discovery and Optimization of Potent and CNS Penetrant M-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. Bender AM, Cho HP, Nance KD, Lingenfelter KS, Luscombe VB, Gentry PR, Voigtritter K, Berizzi AE, Sexton PM, Langmead CJ, Christopoulos A, Locuson CW, Bridges TM, Chang S, O'Neill JC, Zhan X, Niswender CM, Jones CK, Conn PJ, Lindsley CW (2018) ACS Chem Neurosci 9(7): 1572-1581
    › Primary publication · 29678111 (PubMed) · PMC6104635 (PubMed Central)
  31. M-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Moran SP, Dickerson JW, Cho HP, Xiang Z, Maksymetz J, Remke DH, Lv X, Doyle CA, Rajan DH, Niswender CM, Engers DW, Lindsley CW, Rook JM, Conn PJ (2018) Neuropsychopharmacology 43(8): 1763-1771
    › Primary publication · 29581537 (PubMed) · PMC6006294 (PubMed Central)
  32. Differential Pharmacology and Binding of mGlu Receptor Allosteric Modulators. O'Brien DE, Shaw DM, Cho HP, Cross AJ, Wesolowski SS, Felts AS, Bergare J, Elmore CS, Lindsley CW, Niswender CM, Conn PJ (2018) Mol Pharmacol 93(5): 526-540
    › Primary publication · 29545267 (PubMed) · PMC5894801 (PubMed Central)
  33. Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M Muscarinic Receptor as a Novel Therapeutic Target. Gogliotti RG, Fisher NM, Stansley BJ, Jones CK, Lindsley CW, Conn PJ, Niswender CM (2018) J Pharmacol Exp Ther 365(2): 291-300
    › Primary publication · 29523700 (PubMed) · PMC5878667 (PubMed Central)
  34. Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M Muscarinic Receptor. Moehle MS, Pancani T, Byun N, Yohn SE, Wilson GH, Dickerson JW, Remke DH, Xiang Z, Niswender CM, Wess J, Jones CK, Lindsley CW, Rook JM, Conn PJ (2017) Neuron 96(6): 1358-1372.e4
    › Primary publication · 29268098 (PubMed) · PMC5753765 (PubMed Central)
  35. VU6010608, a Novel mGlu NAM from a Series of -(2-(1-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides. Reed CW, McGowan KM, Spearing PK, Stansley BJ, Roenfanz HF, Engers DW, Rodriguez AL, Engelberg EM, Luscombe VB, Loch MT, Remke DH, Rook JM, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW (2017) ACS Med Chem Lett 8(12): 1326-1330
    › Primary publication · 29259756 (PubMed) · PMC5733308 (PubMed Central)
  36. Genetic Reduction or Negative Modulation of mGlu Does Not Impact Anxiety and Fear Learning Phenotypes in a Mouse Model of MECP2 Duplication Syndrome. Fisher NM, Gogliotti RG, Vermudez SAD, Stansley BJ, Conn PJ, Niswender CM (2018) ACS Chem Neurosci 9(9): 2210-2217
    › Primary publication · 29227625 (PubMed) · PMC6002927 (PubMed Central)
  37. When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. Pulley JM, Jerome RN, Zaleski NM, Shirey-Rice JK, Pruijssers AJ, Lavieri RR, Chettiar SN, Naylor HM, Aronoff DM, Edwards DA, Niswender CM, Dugan LL, Crofford LJ, Bernard GR, Holroyd KJ (2017) Assay Drug Dev Technol 15(8): 354-361
    › Primary publication · 29193979 (PubMed) · PMC5731541 (PubMed Central)
  38. Contextual Fear Extinction Induces Hippocampal Metaplasticity Mediated by Metabotropic Glutamate Receptor 5. Stansley BJ, Fisher NM, Gogliotti RG, Lindsley CW, Conn PJ, Niswender CM (2018) Cereb Cortex 28(12): 4291-4304
    › Primary publication · 29136107 (PubMed) · PMC6454528 (PubMed Central)
  39. Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides. Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(23): 5179-5184
    › Primary publication · 29089231 (PubMed) · PMC6542369 (PubMed Central)
  40. Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M positive allosteric modulator (PAM) chemotype via scaffold hopping. Long MF, Engers JL, Chang S, Zhan X, Weiner RL, Luscombe VB, Rodriguez AL, Cho HP, Niswender CM, Bridges TM, Conn PJ, Engers DW, Lindsley CW (2017) Bioorg Med Chem Lett 27(22): 4999-5001
    › Primary publication · 29037946 (PubMed) · PMC5784840 (PubMed Central)
  41. Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Felts AS, Rodriguez AL, Morrison RD, Bollinger KA, Venable DF, Blobaum AL, Byers FW, Thompson Gray A, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2017) Bioorg Med Chem Lett 27(21): 4858-4866
    › Primary publication · 28958625 (PubMed) · PMC5716465 (PubMed Central)
  42. Design and Synthesis of -Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu NAMs. Engers JL, Bollinger KA, Weiner RL, Rodriguez AL, Long MF, Breiner MM, Chang S, Bollinger SR, Bubser M, Jones CK, Morrison RD, Bridges TM, Blobaum AL, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW (2017) ACS Med Chem Lett 8(9): 925-930
    › Primary publication · 28947938 (PubMed) · PMC5601378 (PubMed Central)
  43. Design and Synthesis of mGlu NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. Bollinger KA, Felts AS, Brassard CJ, Engers JL, Rodriguez AL, Weiner RL, Cho HP, Chang S, Bubser M, Jones CK, Blobaum AL, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW (2017) ACS Med Chem Lett 8(9): 919-924
    › Primary publication · 28947937 (PubMed) · PMC5601377 (PubMed Central)
  44. Discovery of a novel, CNS penetrant M PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core. Bewley BR, Spearing PK, Weiner RL, Luscombe VB, Zhan X, Chang S, Cho HP, Rodriguez AL, Niswender CM, Conn PJ, Bridges TM, Engers DW, Lindsley CW (2017) Bioorg Med Chem Lett 27(18): 4274-4279
    › Primary publication · 28866269 (PubMed) · PMC5688877 (PubMed Central)
  45. mGlu potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Gogliotti RG, Senter RK, Fisher NM, Adams J, Zamorano R, Walker AG, Blobaum AL, Engers DW, Hopkins CR, Daniels JS, Jones CK, Lindsley CW, Xiang Z, Conn PJ, Niswender CM (2017) Sci Transl Med 9(403)
    › Primary publication · 28814546 (PubMed) · PMC5654528 (PubMed Central)
  46. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M PAM VU0467154. Gould RW, Grannan MD, Gunter BW, Ball J, Bubser M, Bridges TM, Wess J, Wood MW, Brandon NJ, Duggan ME, Niswender CM, Lindsley CW, Conn PJ, Jones CK (2018) Neuropharmacology : 492-502
    › Primary publication · 28729220 (PubMed) · PMC6756753 (PubMed Central)
  47. Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists. Bender AM, Weiner RL, Luscombe VB, Ajmera S, Cho HP, Chang S, Zhan X, Rodriguez AL, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW (2017) Bioorg Med Chem Lett 27(15): 3576-3581
    › Primary publication · 28633897 (PubMed) · PMC6659418 (PubMed Central)
  48. Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. Felts AS, Rodriguez AL, Blobaum AL, Morrison RD, Bates BS, Thompson Gray A, Rook JM, Tantawy MN, Byers FW, Chang S, Venable DF, Luscombe VB, Tamagnan GD, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2017) J Med Chem 60(12): 5072-5085
    › Primary publication · 28530802 (PubMed) · PMC5484149 (PubMed Central)
  49. Challenges in the development of an M PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Tarr JC, Wood MR, Noetzel MJ, Bertron JL, Weiner RL, Rodriguez AL, Lamsal A, Byers FW, Chang S, Cho HP, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(13): 2990-2995
    › Primary publication · 28522253 (PubMed) · PMC5518475 (PubMed Central)
  50. Optimization of M positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Melancon BJ, Wood MR, Noetzel MJ, Nance KD, Engelberg EM, Han C, Lamsal A, Chang S, Cho HP, Byers FW, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Wu D, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(11): 2296-2301
    › Primary publication · 28442253 (PubMed) · PMC5508548 (PubMed Central)
  51. Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. Bender AM, Weiner RL, Luscombe VB, Cho HP, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW (2017) Bioorg Med Chem Lett 27(11): 2479-2483
    › Primary publication · 28427812 (PubMed) · PMC5508519 (PubMed Central)
  52. Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, Bastarache L, Niu X, Holroyd KJ, Roden DM, Skaar EP, Niswender CM, Marnett LJ, Lindsley CW, Ekstrom LB, Bentley AR, Bernard GR, Hong CC, Denny JC (2017) Assay Drug Dev Technol 15(3): 113-119
    › Primary publication · 28379727 (PubMed) · PMC5399743 (PubMed Central)
  53. Corrigendum to "Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres" [Bioorg. Med. Chem. Lett. 24 (2014) 1062-1066]. Sheffler DJ, Nedelcovych MT, Williams R, Turner SC, Duerk BB, Robbins MR, Jadhav SB, Niswender CM, Jones CK, Conn PJ, Nathan Daniels R, Lindsley CW (2017) Bioorg Med Chem Lett 27(9): 2079
    › Primary publication · 28347668 (PubMed)
  54. Discovery of VU0467485/AZ13713945: An M PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. Wood MR, Noetzel MJ, Melancon BJ, Poslusney MS, Nance KD, Hurtado MA, Luscombe VB, Weiner RL, Rodriguez AL, Lamsal A, Chang S, Bubser M, Blobaum AL, Engers DW, Niswender CM, Jones CK, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) ACS Med Chem Lett 8(2): 233-238
    › Primary publication · 28197318 (PubMed) · PMC5304297 (PubMed Central)
  55. Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core. Nance KD, Days EL, Weaver CD, Coldren A, Farmer TD, Cho HP, Niswender CM, Blobaum AL, Niswender KD, Lindsley CW (2017) J Med Chem 60(4): 1611-1616
    › Primary publication · 28103022 (PubMed)
  56. Diverse Effects on M Signaling and Adverse Effect Liability within a Series of M Ago-PAMs. Rook JM, Abe M, Cho HP, Nance KD, Luscombe VB, Adams JJ, Dickerson JW, Remke DH, Garcia-Barrantes PM, Engers DW, Engers JL, Chang S, Foster JJ, Blobaum AL, Niswender CM, Jones CK, Conn PJ, Lindsley CW (2017) ACS Chem Neurosci 8(4): 866-883
    › Primary publication · 28001356 (PubMed) · PMC5460155 (PubMed Central)
  57. Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Wood MR, Noetzel MJ, Poslusney MS, Melancon BJ, Tarr JC, Lamsal A, Chang S, Luscombe VB, Weiner RL, Cho HP, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2017) Bioorg Med Chem Lett 27(2): 171-175
    › Primary publication · 27939174 (PubMed) · PMC5340297 (PubMed Central)
  58. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ (2016) Neuron 91(6): 1244-1252
    › Primary publication · 27618677 (PubMed) · PMC5033724 (PubMed Central)
  59. Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M PAM VU6004256. Grannan MD, Mielnik CA, Moran SP, Gould RW, Ball J, Lu Z, Bubser M, Ramsey AJ, Abe M, Cho HP, Nance KD, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW, Jones CK (2016) ACS Chem Neurosci 7(12): 1706-1716
    › Primary publication · 27617634 (PubMed) · PMC5231396 (PubMed Central)
  60. Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. Wood MR, Noetzel MJ, Tarr JC, Rodriguez AL, Lamsal A, Chang S, Foster JJ, Smith E, Chase P, Hodder PS, Engers DW, Niswender CM, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2016) Bioorg Med Chem Lett 26(17): 4282-6
    › Primary publication · 27476142 (PubMed) · PMC4987221 (PubMed Central)
  61. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. Niswender CM, Jones CK, Lin X, Bubser M, Thompson Gray A, Blobaum AL, Engers DW, Rodriguez AL, Loch MT, Daniels JS, Lindsley CW, Hopkins CR, Javitch JA, Conn PJ (2016) ACS Chem Neurosci 7(9): 1201-11
    › Primary publication · 27441572 (PubMed) · PMC5073817 (PubMed Central)
  62. The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Senter RK, Ghoshal A, Walker AG, Xiang Z, Niswender CM, Conn PJ (2016) Curr Neuropharmacol 14(5): 455-73
    › Primary publication · 27296640 (PubMed) · PMC4983746 (PubMed Central)
  63. Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4). Gogliotti RD, Blobaum AL, Morrison RM, Daniels JS, Salovich JM, Cheung YY, Rodriguez AL, Loch MT, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2016) Bioorg Med Chem Lett 26(13): 2984-2987
    › Primary publication · 27234146 (PubMed) · PMC4955388 (PubMed Central)
  64. Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core. Wood MR, Noetzel MJ, Engers JL, Bollinger KA, Melancon BJ, Tarr JC, Han C, West M, Gregro AR, Lamsal A, Chang S, Ajmera S, Smith E, Chase P, Hodder PS, Bubser M, Jones CK, Hopkins CR, Emmitte KA, Niswender CM, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW (2016) Bioorg Med Chem Lett 26(13): 3029-3033
    › Primary publication · 27185330 (PubMed) · PMC4955361 (PubMed Central)
  65. Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Panarese JD, Cho HP, Adams JJ, Nance KD, Garcia-Barrantes PM, Chang S, Morrison RD, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(15): 3822-5
    › Primary publication · 27173801 (PubMed) · PMC5082649 (PubMed Central)
  66. Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Gogliotti RD, Engers DW, Garcia-Barrantes PM, Panarese JD, Gentry PR, Blobaum AL, Morrison RD, Daniels JS, Thompson AD, Jones CK, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2016) Bioorg Med Chem Lett 26(12): 2915-2919
    › Primary publication · 27131990 (PubMed) · PMC4899947 (PubMed Central)
  67. Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4). Engers DW, Blobaum AL, Gogliotti RD, Cheung YY, Salovich JM, Garcia-Barrantes PM, Daniels JS, Morrison R, Jones CK, Soars MG, Zhuo X, Hurley J, Macor JE, Bronson JJ, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2016) ACS Chem Neurosci 7(9): 1192-200
    › Primary publication · 27075300 (PubMed) · PMC5031509 (PubMed Central)
  68. Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. Garcia-Barrantes PM, Cho HP, Starr TM, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(9): 2289-92
    › Primary publication · 27013388 (PubMed) · PMC4833523 (PubMed Central)
  69. N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents. Felts AS, Rodriguez AL, Morrison RD, Venable DF, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2016) Bioorg Med Chem Lett 26(8): 1894-900
    › Primary publication · 26988308 (PubMed) · PMC4824313 (PubMed Central)
  70. Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs. Garcia-Barrantes PM, Cho HP, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(8): 1869-72
    › Primary publication · 26988302 (PubMed) · PMC4823774 (PubMed Central)
  71. mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Gogliotti RG, Senter RK, Rook JM, Ghoshal A, Zamorano R, Malosh C, Stauffer SR, Bridges TM, Bartolome JM, Daniels JS, Jones CK, Lindsley CW, Conn PJ, Niswender CM (2016) Hum Mol Genet 25(10): 1990-2004
    › Primary publication · 26936821 (PubMed) · PMC5062588 (PubMed Central)
  72. Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Lindsley CW, Emmitte KA, Hopkins CR, Bridges TM, Gregory KJ, Niswender CM, Conn PJ (2016) Chem Rev 116(11): 6707-41
    › Primary publication · 26882314 (PubMed) · PMC4988345 (PubMed Central)
  73. The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia. Ponnazhagan R, Harms AS, Thome AD, Jurkuvenaite A, Gogliotti R, Niswender CM, Conn PJ, Standaert DG (2016) J Neuroimmune Pharmacol 11(2): 231-7
    › Primary publication · 26872456 (PubMed) · PMC4848139 (PubMed Central)
  74. Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool. Garcia-Barrantes PM, Cho HP, Metts AM, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2016) Bioorg Med Chem Lett 26(3): 751-756
    › Primary publication · 26778256 (PubMed) · PMC4794757 (PubMed Central)
  75. Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Conde-Ceide S, Alcázar J, Alonso de Diego SA, López S, Martín-Martín ML, Martínez-Viturro CM, Pena MA, Tong HM, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Lindsley CW, Bartolomé-Nebreda JM (2016) Bioorg Med Chem Lett 26(2): 429-434
    › Primary publication · 26684851 (PubMed) · PMC4835042 (PubMed Central)
  76. M1 and M3 muscarinic receptors may play a role in the neurotoxicity of anhydroecgonine methyl ester, a cocaine pyrolysis product. Garcia RC, Dati LM, Torres LH, da Silva MA, Udo MS, Abdalla FM, da Costa JL, Gorjão R, Afeche SC, Yonamine M, Niswender CM, Conn PJ, Camarini R, Sandoval MR, Marcourakis T (2015) Sci Rep : 17555
    › Primary publication · 26626425 (PubMed) · PMC4667193 (PubMed Central)
  77. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. Gould RW, Nedelcovych MT, Gong X, Tsai E, Bubser M, Bridges TM, Wood MR, Duggan ME, Brandon NJ, Dunlop J, Wood MW, Ivarsson M, Noetzel MJ, Daniels JS, Niswender CM, Lindsley CW, Conn PJ, Jones CK (2016) Neuropharmacology : 244-53
    › Primary publication · 26617071 (PubMed) · PMC4809053 (PubMed Central)
  78. Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. Felts AS, Rodriguez AL, Smith KA, Engers JL, Morrison RD, Byers FW, Blobaum AL, Locuson CW, Chang S, Venable DF, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Emmitte KA (2015) J Med Chem 58(22): 9027-40
    › Primary publication · 26524606 (PubMed) · PMC4817271 (PubMed Central)
  79. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, Xiang Z, Conn PJ (2015) Proc Natl Acad Sci U S A 112(45): 14078-83
    › Primary publication · 26508634 (PubMed) · PMC4653197 (PubMed Central)
  80. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. Nickols HH, Yuh JP, Gregory KJ, Morrison RD, Bates BS, Stauffer SR, Emmitte KA, Bubser M, Peng W, Nedelcovych MT, Thompson A, Lv X, Xiang Z, Daniels JS, Niswender CM, Lindsley CW, Jones CK, Conn PJ (2016) J Pharmacol Exp Ther 356(1): 123-36
    › Primary publication · 26503377 (PubMed) · PMC4702078 (PubMed Central)
  81. Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core. Garcia-Barrantes PM, Cho HP, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW (2015) Bioorg Med Chem Lett 25(22): 5107-10
    › Primary publication · 26476971 (PubMed) · PMC4758672 (PubMed Central)
  82. Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Malosh C, Turlington M, Bridges TM, Rook JM, Noetzel MJ, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martínez-Viturro CM, Piedrafita M, Sánchez-Casado MR, Macdonald GJ, Daniels JS, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(22): 5115-20
    › Primary publication · 26475522 (PubMed) · PMC4634704 (PubMed Central)
  83. Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics. Garcia-Barrantes PM, Cho HP, Niswender CM, Byers FW, Locuson CW, Blobaum AL, Xiang Z, Rook JM, Conn PJ, Lindsley CW (2015) J Med Chem 58(20): 7959-71
    › Primary publication · 26426481 (PubMed) · PMC4839290 (PubMed Central)
  84. Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. Engers JL, Rodriguez AL, Konkol LC, Morrison RD, Thompson AD, Byers FW, Blobaum AL, Chang S, Venable DF, Loch MT, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2015) J Med Chem 58(18): 7485-500
    › Primary publication · 26335039 (PubMed) · PMC4809247 (PubMed Central)
  85. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Gould RW, Amato RJ, Bubser M, Joffe ME, Nedelcovych MT, Thompson AD, Nickols HH, Yuh JP, Zhan X, Felts AS, Rodriguez AL, Morrison RD, Byers FW, Rook JM, Daniels JS, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW, Jones CK (2016) Neuropsychopharmacology 41(4): 1166-78
    › Primary publication · 26315507 (PubMed) · PMC4748441 (PubMed Central)
  86. Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. Zhou Y, Malosh C, Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolomé-Nebreda JM, Lindsley CW (2015) Bioorg Med Chem Lett 25(17): 3515-9
    › Primary publication · 26183084 (PubMed) · PMC4535329 (PubMed Central)
  87. Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Garcia-Barrantes PM, Lavreysen H, Mackie C, Vinson PN, Rook JM, Bridges TM, Daniels JS, Megens A, Langlois X, Drinkenburg WH, Ahnaou A, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolomé-Nebreda JM, Lindsley CW (2015) ACS Med Chem Lett 6(6): 716-20
    › Primary publication · 26157544 (PubMed) · PMC4492464 (PubMed Central)
  88. Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, Lamsal A, Noetzel MJ, Poslusney MS, Wood MR, Melancon BJ, Stauffer SR, Xiang Z, Daniels JS, Niswender CM, Jones CK, Lindsley CW, Conn PJ (2016) Neuropsychopharmacology 41(2): 598-610
    › Primary publication · 26108886 (PubMed) · PMC5130135 (PubMed Central)
  89. Activation of Metabotropic Glutamate Receptor 7 Is Required for Induction of Long-Term Potentiation at SC-CA1 Synapses in the Hippocampus. Klar R, Walker AG, Ghose D, Grueter BA, Engers DW, Hopkins CR, Lindsley CW, Xiang Z, Conn PJ, Niswender CM (2015) J Neurosci 35(19): 7600-15
    › Primary publication · 25972184 (PubMed) · PMC4429158 (PubMed Central)
  90. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Rook JM, Xiang Z, Lv X, Ghoshal A, Dickerson JW, Bridges TM, Johnson KA, Foster DJ, Gregory KJ, Vinson PN, Thompson AD, Byun N, Collier RL, Bubser M, Nedelcovych MT, Gould RW, Stauffer SR, Daniels JS, Niswender CM, Lavreysen H, Mackie C, Conde-Ceide S, Alcazar J, Bartolomé-Nebreda JM, Macdonald GJ, Talpos JC, Steckler T, Jones CK, Lindsley CW, Conn PJ (2015) Neuron 86(4): 1029-1040
    › Primary publication · 25937172 (PubMed) · PMC4443790 (PubMed Central)
  91. Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). Smith E, Chase P, Niswender CM, Utley TJ, Sheffler DJ, Noetzel MJ, Lamsal A, Wood MR, Conn PJ, Lindsley CW, Madoux F, Acosta M, Scampavia L, Spicer T, Hodder P (2015) J Biomol Screen 20(7): 858-68
    › Primary publication · 25877150 (PubMed) · PMC4659430 (PubMed Central)
  92. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA (2015) Neuropharmacology : 121-9
    › Primary publication · 25749357 (PubMed) · PMC4466038 (PubMed Central)
  93. Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Martín-Martín ML, Bartolomé-Nebreda JM, Conde-Ceide S, Alonso de Diego SA, López S, Martínez-Viturro CM, Tong HM, Lavreysen H, Macdonald GJ, Steckler T, Mackie C, Bridges TM, Daniels JS, Niswender CM, Noetzel MJ, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(6): 1310-7
    › Primary publication · 25683622 (PubMed) · PMC4399811 (PubMed Central)
  94. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Walker AG, Wenthur CJ, Xiang Z, Rook JM, Emmitte KA, Niswender CM, Lindsley CW, Conn PJ (2015) Proc Natl Acad Sci U S A 112(4): 1196-201
    › Primary publication · 25583490 (PubMed) · PMC4313856 (PubMed Central)
  95. Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges. Kurata H, Gentry PR, Kokubo M, Cho HP, Bridges TM, Niswender CM, Byers FW, Wood MR, Daniels JS, Conn PJ, Lindsley CW (2015) Bioorg Med Chem Lett 25(3): 690-4
    › Primary publication · 25542588 (PubMed) · PMC4535335 (PubMed Central)
  96. Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Han C, Chatterjee A, Noetzel MJ, Panarese JD, Smith E, Chase P, Hodder P, Niswender C, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(2): 384-8
    › Primary publication · 25435150 (PubMed) · PMC4278958 (PubMed Central)
  97. Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). Morris LC, Nance KD, Gentry PR, Days EL, Weaver CD, Niswender CM, Thompson AD, Jones CK, Locuson CW, Morrison RD, Daniels JS, Niswender KD, Lindsley CW (2014) J Med Chem 57(23): 10192-7
    › Primary publication · 25423411 (PubMed) · PMC4266362 (PubMed Central)
  98. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2015) Neuropsychopharmacology 40(3): 755-65
    › Primary publication · 25241804 (PubMed) · PMC4289965 (PubMed Central)
  99. Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. Jalan-Sakrikar N, Field JR, Klar R, Mattmann ME, Gregory KJ, Zamorano R, Engers DW, Bollinger SR, Weaver CD, Days EL, Lewis LM, Utley TJ, Hurtado M, Rigault D, Acher F, Walker AG, Melancon BJ, Wood MR, Lindsley CW, Conn PJ, Xiang Z, Hopkins CR, Niswender CM (2014) ACS Chem Neurosci 5(12): 1221-37
    › Primary publication · 25225882 (PubMed) · PMC4306484 (PubMed Central)
  100. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Conn PJ, Lindsley CW, Meiler J, Niswender CM (2014) Nat Rev Drug Discov 13(9): 692-708
    › Primary publication · 25176435 (PubMed) · PMC4208620 (PubMed Central)
  101. Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). Gentry PR, Kokubo M, Bridges TM, Noetzel MJ, Cho HP, Lamsal A, Smith E, Chase P, Hodder PS, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR (2014) J Med Chem 57(18): 7804-10
    › Primary publication · 25147929 (PubMed) · PMC4175000 (PubMed Central)
  102. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, Lamsal A, Niswender CM, Daniels JS, Poslusney MS, Melancon BJ, Tarr JC, Byers FW, Wess J, Duggan ME, Dunlop J, Wood MW, Brandon NJ, Wood MR, Lindsley CW, Conn PJ, Jones CK (2014) ACS Chem Neurosci 5(10): 920-42
    › Primary publication · 25137629 (PubMed) · PMC4324418 (PubMed Central)
  103. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. Cho HP, Garcia-Barrantes PM, Brogan JT, Hopkins CR, Niswender CM, Rodriguez AL, Venable DF, Morrison RD, Bubser M, Daniels JS, Jones CK, Conn PJ, Lindsley CW (2014) ACS Chem Biol 9(10): 2334-46
    › Primary publication · 25137254 (PubMed) · PMC4201332 (PubMed Central)
  104. Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bates BS, Rodriguez AL, Felts AS, Morrison RD, Venable DF, Blobaum AL, Byers FW, Lawson KP, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2014) Bioorg Med Chem Lett 24(15): 3307-14
    › Primary publication · 24969015 (PubMed) · PMC4090943 (PubMed Central)
  105. Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Turlington M, Noetzel MJ, Bridges TM, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Tong HM, Macdonald GJ, Daniels JS, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR (2014) Bioorg Med Chem Lett 24(15): 3641-6
    › Primary publication · 24961642 (PubMed) · PMC4234308 (PubMed Central)
  106. Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅). Turlington M, Malosh C, Jacobs J, Manka JT, Noetzel MJ, Vinson PN, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martín-Martín ML, Tong HM, López S, MacDonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2014) J Med Chem 57(13): 5620-37
    › Primary publication · 24914612 (PubMed) · PMC4096224 (PubMed Central)
  107. A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors. Cho HP, Engers DW, Venable DF, Niswender CM, Lindsley CW, Conn PJ, Emmitte KA, Rodriguez AL (2014) ACS Chem Neurosci 5(7): 597-610
    › Primary publication · 24798819 (PubMed) · PMC4102972 (PubMed Central)
  108. Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. Yin S, Niswender CM (2014) Cell Signal 26(10): 2284-97
    › Primary publication · 24793301 (PubMed) · PMC4130774 (PubMed Central)
  109. Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. Gentry PR, Kokubo M, Bridges TM, Cho HP, Smith E, Chase P, Hodder PS, Utley TJ, Rajapakse A, Byers F, Niswender CM, Morrison RD, Daniels JS, Wood MR, Conn PJ, Lindsley CW (2014) ChemMedChem 9(8): 1677-82
    › Primary publication · 24692176 (PubMed) · PMC4116439 (PubMed Central)
  110. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, Cherezov V, Conn PJ, Stevens RC (2014) Science 344(6179): 58-64
    › Primary publication · 24603153 (PubMed) · PMC3991565 (PubMed Central)
  111. M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's location. Foster DJ, Gentry PR, Lizardi-Ortiz JE, Bridges TM, Wood MR, Niswender CM, Sulzer D, Lindsley CW, Xiang Z, Conn PJ (2014) J Neurosci 34(9): 3253-62
    › Primary publication · 24573284 (PubMed) · PMC3935086 (PubMed Central)
  112. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteres. Sheffler DJ, Nedelcovych MT, Williams R, Turner SC, Duerk BB, Robbins MR, Jadhav SB, Niswender CM, Jones CK, Conn PJ, Daniels RN, Lindsley CW (2014) Bioorg Med Chem Lett 24(4): 1062-6
    › Primary publication · 24462664 (PubMed) · PMC3951244 (PubMed Central)
  113. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Jones CK, Sheffler DJ, Williams R, Jadhav SB, Felts AS, Morrison RD, Niswender CM, Daniels JS, Conn PJ, Lindsley CW (2014) Bioorg Med Chem Lett 24(4): 1067-70
    › Primary publication · 24461352 (PubMed) · PMC3951249 (PubMed Central)
  114. Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. Yin S, Noetzel MJ, Johnson KA, Zamorano R, Jalan-Sakrikar N, Gregory KJ, Conn PJ, Niswender CM (2014) J Neurosci 34(1): 79-94
    › Primary publication · 24381270 (PubMed) · PMC3866496 (PubMed Central)
  115. Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375). Gentry PR, Kokubo M, Bridges TM, Kett NR, Harp JM, Cho HP, Smith E, Chase P, Hodder PS, Niswender CM, Daniels JS, Conn PJ, Wood MR, Lindsley CW (2013) J Med Chem 56(22): 9351-5
    › Primary publication · 24164599 (PubMed) · PMC3876027 (PubMed Central)
  116. Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Felts AS, Rodriguez AL, Morrison RD, Venable DF, Manka JT, Bates BS, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2013) Bioorg Med Chem Lett 23(21): 5779-85
    › Primary publication · 24074843 (PubMed) · PMC3846293 (PubMed Central)
  117. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). Turlington M, Noetzel MJ, Chun A, Zhou Y, Gogliotti RD, Nguyen ED, Gregory KJ, Vinson PN, Rook JM, Gogi KK, Xiang Z, Bridges TM, Daniels JS, Jones C, Niswender CM, Meiler J, Conn PJ, Lindsley CW, Stauffer SR (2013) J Med Chem 56(20): 7976-96
    › Primary publication · 24050755 (PubMed) · PMC3908770 (PubMed Central)
  118. Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Blobaum AL, Bridges TM, Byers FW, Turlington ML, Mattmann ME, Morrison RD, Mackie C, Lavreysen H, Bartolomé JM, Macdonald GJ, Steckler T, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR, Daniels JS (2013) Drug Metab Dispos 41(12): 2066-75
    › Primary publication · 24003250 (PubMed) · PMC3834130 (PubMed Central)
  119. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. Gregory KJ, Herman EJ, Ramsey AJ, Hammond AS, Byun NE, Stauffer SR, Manka JT, Jadhav S, Bridges TM, Weaver CD, Niswender CM, Steckler T, Drinkenburg WH, Ahnaou A, Lavreysen H, Macdonald GJ, Bartolomé JM, Mackie C, Hrupka BJ, Caron MG, Daigle TL, Lindsley CW, Conn PJ, Jones CK (2013) J Pharmacol Exp Ther 347(2): 438-57
    › Primary publication · 23965381 (PubMed) · PMC3807069 (PubMed Central)
  120. Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. Bartolomé-Nebreda JM, Conde-Ceide S, Delgado F, Iturrino L, Pastor J, Pena MÁ, Trabanco AA, Tresadern G, Wassvik CM, Stauffer SR, Jadhav S, Gogi K, Vinson PN, Noetzel MJ, Days E, Weaver CD, Lindsley CW, Niswender CM, Jones CK, Conn PJ, Rombouts F, Lavreysen H, Macdonald GJ, Mackie C, Steckler T (2013) J Med Chem 56(18): 7243-59
    › Primary publication · 23947773 (PubMed) · PMC3924858 (PubMed Central)
  121. Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1. Manka JT, Rodriguez AL, Morrison RD, Venable DF, Cho HP, Blobaum AL, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA (2013) Bioorg Med Chem Lett 23(18): 5091-6
    › Primary publication · 23932792 (PubMed) · PMC3901432 (PubMed Central)
  122. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Xiang Z, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS (2013) Drug Metab Dispos 41(9): 1703-14
    › Primary publication · 23821185 (PubMed) · PMC3876804 (PubMed Central)
  123. ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. Kaufmann K, Romaine I, Days E, Pascual C, Malik A, Yang L, Zou B, Du Y, Sliwoski G, Morrison RD, Denton J, Niswender CM, Daniels JS, Sulikowski GA, Xie XS, Lindsley CW, Weaver CD (2013) ACS Chem Neurosci 4(9): 1278-86
    › Primary publication · 23730969 (PubMed) · PMC3778424 (PubMed Central)
  124. N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Lovell KM, Felts AS, Rodriguez AL, Venable DF, Cho HP, Morrison RD, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA (2013) Bioorg Med Chem Lett 23(13): 3713-8
    › Primary publication · 23727046 (PubMed) · PMC3875306 (PubMed Central)
  125. Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. Amato RJ, Felts AS, Rodriguez AL, Venable DF, Morrison RD, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Jones CK, Emmitte KA (2013) ACS Chem Neurosci 4(8): 1217-28
    › Primary publication · 23682684 (PubMed) · PMC3750677 (PubMed Central)
  126. Discovery of ML326: The first sub-micromolar, selective M5 PAM. Gentry PR, Bridges TM, Lamsal A, Vinson PN, Smith E, Chase P, Hodder PS, Engers JL, Niswender CM, Daniels JS, Conn PJ, Wood MR, Lindsley CW (2013) Bioorg Med Chem Lett 23(10): 2996-3000
    › Primary publication · 23562060 (PubMed) · PMC3634896 (PubMed Central)
  127. Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule. Poslusney MS, Melancon BJ, Gentry PR, Sheffler DJ, Bridges TM, Utley TJ, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Wood MR (2013) Bioorg Med Chem Lett 23(6): 1860-4
    › Primary publication · 23416001 (PubMed) · PMC3594472 (PubMed Central)
  128. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders. Gregory KJ, Noetzel MJ, Niswender CM (2013) Prog Mol Biol Transl Sci : 61-121
    › Primary publication · 23415092 (PubMed)
  129. Approaches for probing allosteric interactions at 7 transmembrane spanning receptors. Klein MT, Vinson PN, Niswender CM (2013) Prog Mol Biol Transl Sci : 1-59
    › Primary publication · 23415091 (PubMed) · PMC5482179 (PubMed Central)
  130. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Noetzel MJ, Gregory KJ, Vinson PN, Manka JT, Stauffer SR, Lindsley CW, Niswender CM, Xiang Z, Conn PJ (2013) Mol Pharmacol 83(4): 835-47
    › Primary publication · 23348500 (PubMed) · PMC3608436 (PubMed Central)
  131. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. Digby GJ, Utley TJ, Lamsal A, Sevel C, Sheffler DJ, Lebois EP, Bridges TM, Wood MR, Niswender CM, Lindsley CW, Conn PJ (2012) ACS Chem Neurosci 3(12): 1025-36
    › Primary publication · 23259038 (PubMed) · PMC3526969 (PubMed Central)
  132. Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule. Melancon BJ, Poslusney MS, Gentry PR, Tarr JC, Sheffler DJ, Mattmann ME, Bridges TM, Utley TJ, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Wood MR (2013) Bioorg Med Chem Lett 23(2): 412-6
    › Primary publication · 23237839 (PubMed) · PMC3534865 (PubMed Central)
  133. Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism. Sheffler DJ, Sevel C, Le U, Lovell KM, Tarr JC, Carrington SJ, Cho HP, Digby GJ, Niswender CM, Conn PJ, Hopkins CR, Wood MR, Lindsley CW (2013) Bioorg Med Chem Lett 23(1): 223-7
    › Primary publication · 23200253 (PubMed) · PMC3525729 (PubMed Central)
  134. Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Le U, Melancon BJ, Bridges TM, Vinson PN, Utley TJ, Lamsal A, Rodriguez AL, Venable D, Sheffler DJ, Jones CK, Blobaum AL, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2013) Bioorg Med Chem Lett 23(1): 346-50
    › Primary publication · 23177787 (PubMed) · PMC3535830 (PubMed Central)
  135. Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. Tarr JC, Turlington ML, Reid PR, Utley TJ, Sheffler DJ, Cho HP, Klar R, Pancani T, Klein MT, Bridges TM, Morrison RD, Blobaum AL, Xiang Z, Daniels JS, Niswender CM, Conn PJ, Wood MR, Lindsley CW (2012) ACS Chem Neurosci 3(11): 884-95
    › Primary publication · 23173069 (PubMed) · PMC3503349 (PubMed Central)
  136. Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold. Rodriguez AL, Zhou Y, Williams R, Weaver CD, Vinson PN, Dawson ES, Steckler T, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2012) Bioorg Med Chem Lett 22(24): 7388-92
    › Primary publication · 23142615 (PubMed) · PMC3539767 (PubMed Central)
  137. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2013) Biol Psychiatry 73(6): 501-9
    › Primary publication · 23140665 (PubMed) · PMC3572342 (PubMed Central)
  138. Synthesis and biological characterization of a series of novel diaryl amide M₁ antagonists. Poslusney MS, Sevel C, Utley TJ, Bridges TM, Morrison RD, Kett NR, Sheffler DJ, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(22): 6923-8
    › Primary publication · 23062550 (PubMed) · PMC3897205 (PubMed Central)
  139. Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Manka JT, Vinson PN, Gregory KJ, Zhou Y, Williams R, Gogi K, Days E, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2012) Bioorg Med Chem Lett 22(20): 6481-5
    › Primary publication · 22981332 (PubMed) · PMC3755010 (PubMed Central)
  140. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM, Conn PJ (2012) Mol Pharmacol 82(5): 860-75
    › Primary publication · 22863693 (PubMed) · PMC3477233 (PubMed Central)
  141. Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012. Melancon BJ, Utley TJ, Sevel C, Mattmann ME, Cheung YY, Bridges TM, Morrison RD, Sheffler DJ, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(15): 5035-40
    › Primary publication · 22749871 (PubMed) · PMC3883446 (PubMed Central)
  142. Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Salovich JM, Vinson PN, Sheffler DJ, Lamsal A, Utley TJ, Blobaum AL, Bridges TM, Le U, Jones CK, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR (2012) Bioorg Med Chem Lett 22(15): 5084-8
    › Primary publication · 22738637 (PubMed) · PMC3401285 (PubMed Central)
  143. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, Xiang Z, Sheffler DJ, Cho HP, Davis AA, Nemirovsky NE, Mennenga SE, Camp BW, Bimonte-Nelson HA, Bode J, Italiano K, Morrison R, Daniels JS, Niswender CM, Olive MF, Lindsley CW, Jones CK, Conn PJ (2012) J Neurosci 32(25): 8532-44
    › Primary publication · 22723693 (PubMed) · PMC3398407 (PubMed Central)
  144. The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Morrison RD, Blobaum AL, Byers FW, Santomango TS, Bridges TM, Stec D, Brewer KA, Sanchez-Ponce R, Corlew MM, Rush R, Felts AS, Manka J, Bates BS, Venable DF, Rodriguez AL, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA, Daniels JS (2012) Drug Metab Dispos 40(9): 1834-45
    › Primary publication · 22711749 (PubMed) · PMC3422546 (PubMed Central)
  145. Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Sheffler DJ, Wenthur CJ, Bruner JA, Carrington SJ, Vinson PN, Gogi KK, Blobaum AL, Morrison RD, Vamos M, Cosford ND, Stauffer SR, Daniels JS, Niswender CM, Conn PJ, Lindsley CW (2012) Bioorg Med Chem Lett 22(12): 3921-5
    › Primary publication · 22607673 (PubMed) · PMC3365510 (PubMed Central)
  146. Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. Mueller R, Dawson ES, Niswender CM, Butkiewicz M, Hopkins CR, Weaver CD, Lindsley CW, Conn PJ, Meiler J (2012) J Mol Model 18(9): 4437-46
    › Primary publication · 22592386 (PubMed) · PMC3766737 (PubMed Central)
  147. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Johnson KA, Jones CK, Tantawy MN, Bubser M, Marvanova M, Ansari MS, Baldwin RM, Conn PJ, Niswender CM (2013) Neuropharmacology : 187-95
    › Primary publication · 22546615 (PubMed) · PMC3432150 (PubMed Central)
  148. Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. Melancon BJ, Gogliotti RD, Tarr JC, Saleh SA, Chauder BA, Lebois EP, Cho HP, Utley TJ, Sheffler DJ, Bridges TM, Morrison RD, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(10): 3467-72
    › Primary publication · 22507963 (PubMed) · PMC3348459 (PubMed Central)
  149. Functional selectivity induced by mGlu₄ receptor positive allosteric modulation and concomitant activation of Gq coupled receptors. Yin S, Zamorano R, Conn PJ, Niswender CM (2013) Neuropharmacology : 122-32
    › Primary publication · 22426233 (PubMed) · PMC3412075 (PubMed Central)
  150. Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound. Mueller R, Dawson ES, Meiler J, Rodriguez AL, Chauder BA, Bates BS, Felts AS, Lamb JP, Menon UN, Jadhav SB, Kane AS, Jones CK, Gregory KJ, Niswender CM, Conn PJ, Olsen CM, Winder DG, Emmitte KA, Lindsley CW (2012) ChemMedChem 7(3): 406-14
    › Primary publication · 22267125 (PubMed) · PMC3517057 (PubMed Central)
  151. Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012. Melancon BJ, Lamers AP, Bridges TM, Sulikowski GA, Utley TJ, Sheffler DJ, Noetzel MJ, Morrison RD, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Wood MR (2012) Bioorg Med Chem Lett 22(2): 1044-8
    › Primary publication · 22197142 (PubMed) · PMC3434972 (PubMed Central)
  152. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW (2012) J Med Chem 55(4): 1445-64
    › Primary publication · 22148748 (PubMed) · PMC3349997 (PubMed Central)
  153. MAOS ls for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. Aldrich LN, Lebois EP, Lewis LM, Nalywajko NT, Niswender CM, Weaver CD, Conn PJ, Lindsley CW (2009) Tetrahedron Lett 50(2): 212-215
    › Primary publication · 22090663 (PubMed) · PMC3214729 (PubMed Central)
  154. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM (2012) J Pharmacol Exp Ther 340(2): 404-21
    › Primary publication · 22088953 (PubMed) · PMC3263969 (PubMed Central)
  155. Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected 'molecular switch' from a closely related mGlu4 positive allosteric modulator. Utley T, Haddenham D, Salovich JM, Zamorano R, Vinson PN, Lindsley CW, Hopkins CR, Niswender CM (2011) Bioorg Med Chem Lett 21(23): 6955-9
    › Primary publication · 22030026 (PubMed) · PMC3319082 (PubMed Central)
  156. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, Conn PJ (2012) Mol Pharmacol 81(2): 120-33
    › Primary publication · 22021324 (PubMed) · PMC3263948 (PubMed Central)
  157. Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Bogenpohl J, Smith Y, Morrison R, Daniels JS, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) J Med Chem 54(21): 7639-47
    › Primary publication · 21966889 (PubMed) · PMC3226828 (PubMed Central)
  158. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW (2010) ACS Chem Neurosci 1(2): 104-121
    › Primary publication · 21961051 (PubMed) · PMC3180826 (PubMed Central)
  159. Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata. Johnson KA, Niswender CM, Conn PJ, Xiang Z (2011) Neurosci Lett 504(2): 102-106
    › Primary publication · 21945652 (PubMed) · PMC3556513 (PubMed Central)
  160. Cell-type specific expression of a dominant negative PKA mutation in mice. Willis BS, Niswender CM, Su T, Amieux PS, McKnight GS (2011) PLoS One 6(4): e18772
    › Primary publication · 21533282 (PubMed) · PMC3075275 (PubMed Central)
  161. Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄. Cheung YY, Zamorano R, Blobaum AL, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) ACS Comb Sci 13(2): 159-65
    › Primary publication · 21338051 (PubMed) · PMC3057427 (PubMed Central)
  162. Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Williams R, Manka JT, Rodriguez AL, Vinson PN, Niswender CM, Weaver CD, Jones CK, Conn PJ, Lindsley CW, Stauffer SR (2011) Bioorg Med Chem Lett 21(5): 1350-3
    › Primary publication · 21315585 (PubMed) · PMC3498823 (PubMed Central)
  163. Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. Engers DW, Field JR, Le U, Zhou Y, Bolinger JD, Zamorano R, Blobaum AL, Jones CK, Jadhav S, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) J Med Chem 54(4): 1106-10
    › Primary publication · 21247167 (PubMed) · PMC3166797 (PubMed Central)
  164. Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Reid PR, Bridges TM, Sheffler DJ, Cho HP, Lewis LM, Days E, Daniels JS, Jones CK, Niswender CM, Weaver CD, Conn PJ, Lindsley CW, Wood MR (2011) Bioorg Med Chem Lett 21(9): 2697-701
    › Primary publication · 21194936 (PubMed) · PMC3082000 (PubMed Central)
  165. Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. Lamb JP, Engers DW, Niswender CM, Rodriguez AL, Venable DF, Conn PJ, Lindsley CW (2011) Bioorg Med Chem Lett 21(9): 2711-4
    › Primary publication · 21183344 (PubMed) · PMC3179182 (PubMed Central)
  166. Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. Hammond AS, Rodriguez AL, Townsend SD, Niswender CM, Gregory KJ, Lindsley CW, Conn PJ (2010) ACS Chem Neurosci 1(10): 702-716
    › Primary publication · 20981342 (PubMed) · PMC2957851 (PubMed Central)
  167. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ (2010) Mol Pharmacol 78(6): 1105-23
    › Primary publication · 20923853 (PubMed) · PMC2993468 (PubMed Central)
  168. Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Engers DW, Gentry PR, Williams R, Bolinger JD, Weaver CD, Menon UN, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2010) Bioorg Med Chem Lett 20(17): 5175-8
    › Primary publication · 20667732 (PubMed) · PMC2922490 (PubMed Central)
  169. Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. Williams R, Zhou Y, Niswender CM, Luo Q, Conn PJ, Lindsley CW, Hopkins CR (2010) ACS Chem Neurosci 1(6): 411-419
    › Primary publication · 20582156 (PubMed) · PMC2889702 (PubMed Central)
  170. mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. Hopkins CR, Lindsley CW, Niswender CM (2009) Future Med Chem 1(3): 501-13
    › Primary publication · 20161443 (PubMed) · PMC2790174 (PubMed Central)
  171. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Niswender CM, Conn PJ (2010) Annu Rev Pharmacol Toxicol : 295-322
    › Primary publication · 20055706 (PubMed) · PMC2904507 (PubMed Central)
  172. Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Niswender CM, Johnson KA, Miller NR, Ayala JE, Luo Q, Williams R, Saleh S, Orton D, Weaver CD, Conn PJ (2010) Mol Pharmacol 77(3): 459-68
    › Primary publication · 20026717 (PubMed) · PMC2835423 (PubMed Central)
  173. Discovery and development of a potent and highly selective small molecule muscarinic acetylcholine receptor subtype I (mAChR 1 or M1) antagonist in vitro and in vivo probe. Weaver CD, Sheffler DJ, Lewis LM, Bridges TM, Williams R, Nalywajko NT, Kennedy JP, Mulder MM, Jadhav S, Aldrich LA, Jones CK, Marlo JE, Niswender CM, Mock MM, Zheng F, Conn PJ, Lindsley CW (2009) Curr Top Med Chem 9(13): 1217-26
    › Primary publication · 19807667 (PubMed) · PMC4765323 (PubMed Central)
  174. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. Lindsley CW, Niswender CM, Engers DW, Hopkins CR (2009) Curr Top Med Chem 9(10): 949-63
    › Primary publication · 19754407 (PubMed)
  175. Glutamate receptors as therapeutic targets for Parkinson's disease. Johnson KA, Conn PJ, Niswender CM (2009) CNS Neurol Disord Drug Targets 8(6): 475-91
    › Primary publication · 19702565 (PubMed) · PMC3005251 (PubMed Central)
  176. Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4). Williams R, Johnson KA, Gentry PR, Niswender CM, Weaver CD, Conn PJ, Lindsley CW, Hopkins CR (2009) Bioorg Med Chem Lett 19(17): 4967-70
    › Primary publication · 19640716 (PubMed) · PMC2752865 (PubMed Central)
  177. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). Engers DW, Niswender CM, Weaver CD, Jadhav S, Menon UN, Zamorano R, Conn PJ, Lindsley CW, Hopkins CR (2009) J Med Chem 52(14): 4115-8
    › Primary publication · 19469556 (PubMed) · PMC2765192 (PubMed Central)
  178. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. Bridges TM, Marlo JE, Niswender CM, Jones CK, Jadhav SB, Gentry PR, Plumley HC, Weaver CD, Conn PJ, Lindsley CW (2009) J Med Chem 52(11): 3445-8
    › Primary publication · 19438238 (PubMed) · PMC3875304 (PubMed Central)
  179. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Sheffler DJ, Williams R, Bridges TM, Xiang Z, Kane AS, Byun NE, Jadhav S, Mock MM, Zheng F, Lewis LM, Jones CK, Niswender CM, Weaver CD, Lindsley CW, Conn PJ (2009) Mol Pharmacol 76(2): 356-68
    › Primary publication · 19407080 (PubMed) · PMC2713127 (PubMed Central)
  180. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Williams R, Niswender CM, Luo Q, Le U, Conn PJ, Lindsley CW (2009) Bioorg Med Chem Lett 19(3): 962-6
    › Primary publication · 19097893 (PubMed) · PMC3787871 (PubMed Central)
  181. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ (2009) Mol Pharmacol 75(3): 577-88
    › Primary publication · 19047481 (PubMed) · PMC2684909 (PubMed Central)
  182. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Niswender CM, Lebois EP, Luo Q, Kim K, Muchalski H, Yin H, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(20): 5626-30
    › Primary publication · 18793851 (PubMed) · PMC3182458 (PubMed Central)
  183. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ (2008) Mol Pharmacol 74(5): 1345-58
    › Primary publication · 18664603 (PubMed) · PMC2574552 (PubMed Central)
  184. Melanocyte-lineage expression of Cre recombinase using Mitf regulatory elements. Alizadeh A, Fitch KR, Niswender CM, McKnight GS, Barsh GS (2008) Pigment Cell Melanoma Res 21(1): 63-9
    › Primary publication · 18353144 (PubMed)
  185. Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Ayala JE, Niswender CM, Luo Q, Banko JL, Conn PJ (2008) Neuropharmacology 54(5): 804-14
    › Primary publication · 18255102 (PubMed) · PMC2431171 (PubMed Central)
  186. Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Lewis LM, Sheffler D, Williams R, Bridges TM, Kennedy JP, Brogan JT, Mulder MJ, Williams L, Nalywajko NT, Niswender CM, Weaver CD, Conn PJ, Lindsley CW (2008) Bioorg Med Chem Lett 18(3): 885-90
    › Primary publication · 18178088 (PubMed) · PMC2275053 (PubMed Central)
  187. A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ, Weaver CD (2008) Mol Pharmacol 73(4): 1213-24
    › Primary publication · 18171729 (PubMed)
  188. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ (2008) Nat Chem Biol 4(1): 42-50
    › Primary publication · 18059262 (PubMed)
  189. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. Hemstapat K, Da Costa H, Nong Y, Brady AE, Luo Q, Niswender CM, Tamagnan GD, Conn PJ (2007) J Pharmacol Exp Ther 322(1): 254-64
    › Primary publication · 17416742 (PubMed)
  190. mGluR7's lucky number. Conn PJ, Niswender CM (2006) Proc Natl Acad Sci U S A 103(2): 251-2
    › Primary publication · 16407154 (PubMed) · PMC1326193 (PubMed Central)
  191. New therapeutic frontiers for metabotropic glutamate receptors. Niswender CM, Jones CK, Conn PJ (2005) Curr Top Med Chem 5(9): 847-57
    › Primary publication · 16178730 (PubMed)
  192. Cre recombinase-dependent expression of a constitutively active mutant allele of the catalytic subunit of protein kinase A. Niswender CM, Willis BS, Wallen A, Sweet IR, Jetton TL, Thompson BR, Wu C, Lange AJ, McKnight GS (2005) Genesis 43(3): 109-19
    › Primary publication · 16155866 (PubMed)
  193. Protein engineering of protein kinase A catalytic subunits results in the acquisition of novel inhibitor sensitivity. Niswender CM, Ishihara RW, Judge LM, Zhang C, Shokat KM, McKnight GS (2002) J Biol Chem 277(32): 28916-22
    › Primary publication · 12034735 (PubMed)
  194. Strategies and requirements for the detection of RNA editing in G protein coupled-receptor RNA. Niswender CM (2002) Methods Enzymol : 476-92
    › Primary publication · 11665586 (PubMed)
  195. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP (2001) Br J Pharmacol 134(2): 386-92
    › Primary publication · 11564657 (PubMed) · PMC1572953 (PubMed Central)
  196. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E (2001) Neuropsychopharmacology 24(5): 478-91
    › Primary publication · 11282248 (PubMed)
  197. Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. Herrick-Davis K, Grinde E, Niswender CM (1999) J Neurochem 73(4): 1711-7
    › Primary publication · 10501219 (PubMed)
  198. Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Backstrom JR, Chang MS, Chu H, Niswender CM, Sanders-Bush E (1999) Neuropsychopharmacology 21(2 Suppl): 77S-81S
    › Primary publication · 10432492 (PubMed)
  199. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E (1999) J Biol Chem 274(14): 9472-8
    › Primary publication · 10092629 (PubMed)
  200. Identification and characterization of RNA editing events within the 5-HT2C receptor. Niswender CM, Sanders-Bush E, Emeson RB (1998) Ann N Y Acad Sci : 38-48
    › Primary publication · 9928237 (PubMed)
  201. Recent advances in mammalian RNA editing. Niswender CM (1998) Cell Mol Life Sci 54(9): 946-64
    › Primary publication · 9791538 (PubMed)